Waters Corporation Investor Presentation — January 2020

Document content

2020Waters Corporation

Management Presentation

J.P. Morgan 38th Annual Healthcare Conference

Chris O’Connell, Chairman & CEO2 ©2020 Waters CorporationThis presentation may contain “forward -looking” statements regarding future results and events. For this purpose, any statements that are not statements of

historical fact may be deemed forward -looking statements. Without limiting the foregoing, the words, “may”, will”, “should”, “f eels”, “believes”, “anticipates”,

“plans”, “expects”, “intends”, “suggests”, “appears”, “estimates”, “projects”, and similar expressions, whether in the negati ve or affirmative, are intended to

identify forward -looking statements.

Forward -looking statements are based on current expectations and assumptions and currently available data and are neither predic tions nor guarantees of

future events or performance. You should not place undue reliance on forward -looking statements, which speak only as of the dat e hereof and should not

be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this presentation. We do not undertake to

update or revise any forward -looking statements after they are made, whether as a result of new information, future events, or o therwise, except as required

by applicable law. The Company’s actual future results may differ significantly from the results discussed in the forward -looking statements within this

presentation for a variety of reasons, including and without limitation, foreign exchange rate fluctuations potentially affec ting translation of the Company’s

future non -U.S. operating results; the impact on demand for the Company’s products among the Company’s various market sectors or geographies from

economic, sovereign and political uncertainties, particularly regarding the effect of new or proposed tariff or trade regulat ions or changes in interpretation or

enforcement of existing regulations; the effect on the Company’s financial results from the United Kingdom voting to exit the European Union; fluctuations in

expenditures by the Company’s customers, in particular large pharmaceutical companies; introduction of competing products by other companies and loss

of market share; pressures on prices from competitors and/or customers; regulatory, economic and competitive obstacles to new product introductions;

other changes in demand for the Company’s products from the effect of mergers and acquisitions by the Company’s customers; in creased regulatory

burdens as the Company’s business evolves, especially with respect to the U.S. Food and Drug Administration and U.S. Environm ental Protection Agency,